Overview A Study of ATRA in the Treatment of ITP Status: Not yet recruiting Trial end date: 2021-10-01 Target enrollment: Participant gender: Summary An open-label, multicenter study to compare the efficacy and safety of ATRA for the treatment of adults with primary immune thrombocytopenia (ITP) Phase: Phase 2 Details Lead Sponsor: Peking University People's HospitalCollaborators: Beijing HospitalQilu Hospital of Shandong UniversityThe Sixth Medical Center of PLA General HospitalTreatments: Tretinoin